Breast Cancer Therapeutics Market Revenue Growth Predicted by 2018-2026 | AstraZeneca, Eli Lilly and Company, Eisai, F. Hoffmann-La Roche AG, GlaxoSmithKline, Pfizer

According to Breast Cancer Organization, an estimated 252,710 new cases of breast cancer are expected to be identified in the U.S., of which 63,410 cases would be non-invasive breast cancer in 2017. In the U.S., breast cancer death rates are higher than those for any other cancer, besides lung cancer among women. Breast cancer is especially prevalent among women under 45 years of age and African American women rather than white women.

Globally breast cancer is the most common cancer in women, with a prevalence of around 1.7 million in 2012, the second-most common cancer overall. This represents 12% of all new cancer cases and 25% of all cancers in women. Belgium had the topmost rate of breast cancer, followed by Denmark and France, respectively. Marginally less number of cases of breast cancer were diagnosed in less developed countries. The highest occurrence of this type of cancer was in Northern America and Oceania, whereas the lowest incidence rate in Asia and Africa.

Request For Sample Copy Of This Research Report: www.coherentmarketinsights.com/insight/request-sample/250

Cancer is essentially the uncontrolled growth of certain cells in the body that crowd out normal cells over time. When cells in the breast begin to grow out of control it may lead to breast cancer. These cells generally form a tumor that can felt as a lump, which can further be confirmed using a mammogram. The tumor is malignant if the cells can grow into surrounding tissues or spread to other parts of the body. Breast cancer occurs almost entirely in women, though men can also contract breast cancer. Mutations in DNA can cause normal breast cells to become cancerous cells. Some DNA changes are passed on from parents and can significantly increase the threat for breast cancer. Moreover, lifestyle related risk factors such as consumption of fast food and lack of exercise can increase chances of developing breast cancer. However, the exact cause of the disease is yet unknown.

Increasing occurrence of the disease especially in the Developed countries will drive growth of the breast cancer therapeutics market
According to World Health Organization statistics, breast cancer is the second-most predominant type (whereas lung cancer is first) of the disease globally, and the most common type in females. In women, this type of cancer accounts for 20% of all invasive and 13% of all female cancers, and is responsible for 15% of deaths caused by the disease globally, including females and males. Every year, around 200,000 new cases in women and approximately 2,000 new cases are diagnosed in men.

Download The PDF Brochure: www.coherentmarketinsights.com/insight/request-pdf/250

Innovation of therapy with improved success rate is expected to offer lucrative growth opportunities for market players. Despite high costs involved in research and development, pharmaceutical companies are showing increased interest in this field. This is expected to offer good potential for breast cancer therapeutics market.

Key players operating in the global breast cancer therapeutics market are AstraZeneca plc, Eli Lilly and Company, Eisai Co., Ltd., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Pfizer, Inc., Novartis International AG, Puma Biotechnology, Sanofi S.A., and Teva Pharmaceutical Industries.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr.Shah
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.